Expert Video - What is the outlook for AML-MRC, tAML, and secondary AML?
Acute myeloid leukemia expert Dr. Sandra Kurtin explains that the outlook for people with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), treatment-related AML (tAML) or secondary myelodysplastic syndrome (secondary MDS) is usually less good than for de novo AML. People who can have a stem cell transplant, also called a bone marrow transplant, have a better outlook with these secondary types of AML. Clinical trials of new treatments may also improve the outlook for AML-MRC, tAML and secondary AML.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.
Please rate this content:
Other Modules:
1.
Animation - Understanding AML-MRC and tAML
2.
Slide Show - Understanding AML-MRC and tAML
3.
What is AML with myelodysplasia-related changes (AML-MRC)?
4.
What is treatment-related AML (or tAML)?
5.
What is secondary AML?
6.
What are the symptoms of AML-MRC or tAML?
7.
What are the risk factors for AML-MRC or tAML?
8.
What is multilineage dysplasia?
9.
What is the outlook for AML-MRC, tAML, and secondary AML?
10.
Mike's story: How did you find out you had AML?
11.
Mike's story: What advice do you have for other patients on their journey with AML?
